« Back
Home /
Vipivotide tetraxetan

Vipivotide tetraxetan

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	10 mg
Quantity options	10mM/1mL 10 mg 1mg 25 mg 2 mg 50 mg 5 mg
Item no.	HY-117410-10mg
Targets	Drug-Linker Conjugates for ADC
CASRN	1702967-37-0
eClass 6.1	30220300
eClass 9.0	32160605
Available
Alias	PSMA-617
Purity	99.57
Product Description	Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	1042.14
Clinical_Information	Phase 4
Manufacturers Research Area	Cancer
Solubility	DMSO : 125 mg/mL (ultrasonic)\|H2O : ≥ 100 mg/mL
Manufacturers Target	Drug-Linker Conjugates for ADC
Isoform	Traditional Cytotoxic Agents
Pathway	Antibody-drug Conjugate/ADC Related

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-117410-10mg-safety-datasheet.pdf